Management of Hypokalemia with Elevated Aldosterone and Low Renin Levels

Diagnostic Interpretation

The combination of hypokalemia, elevated aldosterone, and suppressed renin creates an elevated aldosterone-to-renin ratio (ARR), which is the recommended screening test for primary aldosteronism, according to the European Society of Cardiology and the American Heart Association 3, 4
Primary aldosteronism occurs in 5-10% of all hypertensive patients and up to 20% of patients with resistant hypertension, as reported by the American College of Cardiology 5
Hypophosphatemia is consistent with primary aldosteronism, as excessive aldosterone can increase urinary phosphate excretion, as noted by the American Heart Association 4

Confirmatory testing is required to establish the diagnosis of primary aldosteronism, as recommended by the European Society of Hypertension and the American Heart Association 3
The ARR is considered positive when the ratio is elevated (typically >30) with a plasma aldosterone concentration of at least 10 ng/dL, according to the Endocrine Society 6

Mineralocorticoid receptor antagonists are the first-line medical treatment for primary aldosteronism, as recommended by the European Society of Cardiology and the American College of Cardiology 1, 2
Spironolactone is the primary agent, starting at 25-50 mg daily, titrating up to 100-400 mg daily as needed, as suggested by the American Heart Association 6

Adrenal venous sampling is recommended before surgical treatment to distinguish between unilateral and bilateral disease, as recommended by the Endocrine Society and the American College of Surgeons 6

Beta-blockers, alpha-2 agonists, and NSAIDs can falsely elevate the ARR by suppressing renin, as noted by the European Society of Cardiology and the American Heart Association 1

Monitor serum potassium levels closely, especially during initiation of mineralocorticoid receptor antagonist therapy, as recommended by the American Heart Association and the National Kidney Foundation 6
Evaluate for resolution of target organ damage over time, such as left ventricular hypertrophy and kidney function, as suggested by the American College of Cardiology and the American Heart Association 5